IO Biotech Upgraded to Buy, Financial Runway Extends to 2026
Piper Sandler upgraded IO Biotech, Inc. (NASDAQ:IOBT) to a Zacks Rank #2 (Buy), reflecting increased optimism for the company's earnings prospects. The biopharmaceutical firm also reported a stable financial position, with operations funded into the first quarter of 2026.
The company held approximately $28.1 million in cash and cash equivalents at the end of the second quarter of 2025. Its financial runway was extended by an additional €12.5 million received from a European Investment Bank loan facility, supporting ongoing clinical trials and development activities.
Despite the analyst upgrade, the consensus price target for IOBT stock has held steady at $3. This stability comes as IO Biotech prepares to meet with the FDA to discuss its pivotal Phase 3 trial for Cylembio® in combination with KEYTRUDA® for treating advanced melanoma. The trial demonstrated a clinical improvement in progression-free survival but did not achieve statistical significance.
IO Biotech is a clinical-stage company developing immune-modulating therapies for cancer. Its lead product candidate, IO102-IO103, is in phase 2 trials for melanoma. For more details, see the company's financial health and investor profile.
IO Biotech, Inc. (IOBT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.